Colorectal Cancer with the BRAF V600E Mutation: Two Case Reports and Literature Review

被引：0

作者：

Pham, Nguyen Cuong ^{[1
]}

Ho, Van Linh ^{[2
]}

Ton-Nu, Victoria ^{[3
]}

Ngo, Minh Tri ^{[4
]}

Nguyen, Huu Son ^{[5
]}

机构：

[1] Hue Cent Hosp, Pathol Dept, Hue City, Vietnam

[2] Hue Cent Hosp, Digest Surg Dept, Hue City, Vietnam

[3] Univ Calif Irvine, Irvine, CA USA

[4] Hue Cent Hosp, Dept Radiol, Hue City, Vietnam

[5] Hue Cent Hosp, Pediat Ctr, Hue City, Vietnam

来源：

INTERNATIONAL JOURNAL OF BIOMEDICINE | 2024年 / 14卷 / 03期

关键词：

rectal cancer; RAS genes; BRAF V600E mutation; FOLFIRI PLUS BEVACIZUMAB; PHASE-II TRIAL; 1ST-LINE TREATMENT; RAS MUTATIONS; COLON-CANCER; POOLED ANALYSIS; BRAF-MUTATION; CETUXIMAB; KRAS; OXALIPLATIN;

D O I：

10.21103/Article14(3)_CRI

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Colorectal cancer usually develops from stepwise, multiple mutations involving oncogenes and tumor suppressor genes. Mutations in the BRAF and RAS genes that dysregulate MAPK signaling are strongly associated with human malignancies. Colorectal cancer with the BRAF V600E mutation that causes cell proliferation without the need for growth factors has a worse prognosis than those without mutations. A BRAF V600E mutation was identified as an adverse prognostic factor for progression-free and overall survival. In this study, we analyze two cases of colorectal cancer with the BRAF V600E mutation and the literature data to investigate potential pathophysiologic mechanisms underlying metastatic colorectal cancer.

引用

页数：182

共 44 条

[1] Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again [J].

Abankwa, Daniel ;

Gorfe, Alemayehu A. .

BIOMOLECULES, 2020, 10 (11)

[2] The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis [J].

Ardekani, Gholamreza Safaee ;

Jafarnejad, Seyed Mehdi ;

Tan, Larry ;

Saeedi, Ardavan ;

Li, Gang .

PLOS ONE, 2012, 7 (10)

[3] Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer [J].

Bardelli, Alberto ;

Siena, Salvatore .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1254-1261

[4]

Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248

[5] Colon Cancer, Version 2.2021 [J].

Benson, Al B. ;

Venook, Alan P. ;

Al-Hawary, Mahmoud M. ;

Arain, Mustafa A. ;

Chen, Yi-Jen ;

Ciombor, Kristen K. ;

Cohen, Stacey ;

Cooper, Harry S. ;

Deming, Dustin ;

Farkas, Linda ;

Garrido-Laguna, Ignacio ;

Grem, Jean L. ;

Gunn, Andrew ;

Hecht, J. Randolph ;

Hoffe, Sarah ;

Hubbard, Joleen ;

Hunt, Steven ;

Johung, Kimberly L. ;

Kirilcuk, Natalie ;

Krishnamurthi, Smitha ;

Messersmith, Wells A. ;

Meyerhardt, Jeffrey ;

Miller, Eric D. ;

Mulcahy, Mary F. ;

Nurkin, Steven ;

Overman, Michael J. ;

Parikh, Aparna ;

Patel, Hitendra ;

Pedersen, Katrina ;

Saltz, Leonard ;

Schneider, Charles ;

Shibata, David ;

Skibber, John M. ;

Sofocleous, Constantinos T. ;

Stoffel, Elena M. ;

Stotsky-Himelfarb, Eden ;

Willett, Christopher G. ;

Gregory, Kristina M. ;

Gurski, Lisa A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03) :329-359

[6] Beyond Exon 2-The Developing Story of RAS Mutations in Colorectal Cancer [J].

Berlin, Jordan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1059-1060

[7] Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials [J].

Bokemeyer, Carsten ;

Van Cutsem, Eric ;

Rougier, Philippe ;

Ciardiello, Fortunato ;

Heeger, Steffen ;

Schlichting, Michael ;

Celik, Ilhan ;

Koehne, Claus-Henning .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) :1466-1475

[8] Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK [J].

Borner, M. ;

Koeberle, D. ;

Von Moos, R. ;

Saletti, P. ;

Rauch, D. ;

Hess, V. ;

Trojan, A. ;

Helbling, D. ;

Pestalozzi, B. ;

Caspar, C. ;

Ruhstaller, T. ;

Roth, A. ;

Kappeler, A. ;

Dietrich, D. ;

Lanz, D. ;

Mingrone, W. .

ANNALS OF ONCOLOGY, 2008, 19 (07) :1288-1292

[9] Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer [J].

Cremolini, Chiara ;

Antoniotti, Carlotta ;

Stein, Alexander ;

Bendell, Johanna ;

Gruenberger, Thomas ;

Rossini, Daniele ;

Masi, Gianluca ;

Ongaro, Elena ;

Hurwitz, Herbert ;

Falcone, Alfredo ;

Schmoll, Hans-Joachim ;

Di Maio, Massimo .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) :3314-3324

[10] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J].

Cremolini, Chiara ;

Loupakis, Fotios ;

Antoniotti, Carlotta ;

Lupi, Cristiana ;

Sensi, Elisa ;

Lonardi, Sara ;

Mezi, Silvia ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Carlomagno, Chiara ;

Allegrini, Giacomo ;

Chiara, Silvana ;

D'Amico, Mauro ;

Granetto, Cristina ;

Cazzaniga, Marina ;

Boni, Luca ;

Fontanini, Gabriella ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2015, 16 (13) :1306-1315

← 1 2 3 4 5 →